Overview of Tiartan

Quick Facts

Property	Description
Active Ingredients	Eprosartan mesylate, Hydrochlorothiazide
Form	Oral Solid Tablet (Film-Coated)
Pharmacological Class	Antihypertensive Combination Agent
General Purpose	Management of High Blood Pressure (Hypertension)
Origin	Synthetic Small Molecule Components

What Type of Medicine is Tiartan?

Tiartan is classified as a synthetic fixed-dose combination (FDC) product that falls within the therapeutic category of antihypertensive agents, used specifically for the management of high blood pressure. It is supplied as an oral solid tablet designed for administration by mouth. This FDC approach is clinically recognized for optimizing patient adherence over multiple-pill regimens, leveraging the combined therapeutic effects of two major drug classes in one pill to provide a comprehensive treatment strategy.

What are the Active Ingredients in Tiartan?

The medication contains two distinct active ingredients: Eprosartan mesylate and Hydrochlorothiazide. Eprosartan mesylate functions as an Angiotensin II Receptor Blocker (ARB), for its ability to selectively target the mechanism that causes blood vessels to tighten. Hydrochlorothiazide is a Thiazide diuretic, which targets the kidneys to promote the increased excretion of salt and water. Both compounds are chemically defined synthetic small molecules, ensuring consistent potency and stability in the final tablet form. A well-known alternative formulation containing the same combination is sometimes marketed under the trade name Teveten Plus or Teveten HCT.

What is the General Purpose of This Combination?

The general therapeutic purpose of using this fixed-dose combination is to achieve effective and sustained control of hypertension. The simultaneous effects—Eprosartan relaxing blood vessels and Hydrochlorothiazide reducing fluid volume—create a synergistic effect that is often more reliable than using either single agent alone. This dual action addresses both the resistance and volume components of high blood pressure, helping to maintain a lower blood pressure profile and mitigating the systemic strain associated with chronic hypertension.

Regulatory References

Teveten HCT DailyMed Monograph

What side effects are possible with Tiartan?

Adverse Reaction Scope

The safety profile of Tiartan, a combination of Eprosartan and Hydrochlorothiazide, is based on reactions documented in official regulatory labeling. Side effects are classified primarily by frequency and affected System-Organ Classes.

Component	Description
Frequency classification	Common reactions (affecting ge 1/100 to < 1/10 patients) typically include headache, dizziness, fatigue, dry cough, upper respiratory infection, and abdominal pain. Other effects are reported at lower frequencies or during post-marketing surveillance [1.1].
System-organ classes involved	Documented effects affect the Nervous System (headache, dizziness), Vascular/Cardiac (hypotension, palpitations), Metabolism and Nutrition (electrolyte imbalances, hyperuricemia), and Eye Disorders (acute transient myopia, secondary angle-closure glaucoma) [1.7, 2.4].
Serious adverse reactions	Officially documented risks include Angioedema, Acute Respiratory Distress Syndrome (ARDS), and Fetal/Neonatal Injury or Death when used during the second and third trimesters of pregnancy [1.1, 1.7].

Safety Classifications (High-Level)

Component	Description
Population-specific safety considerations	The medicine is contraindicated in the 2nd and 3rd trimesters of pregnancy [1.1]. Absolute limitations also exist for individuals with anuria and severe hepatic impairment [1.1, 2.3].
Dose- or exposure-related patterns	Certain acute ocular events may occur rapidly following treatment initiation. Additionally, long-term exposure to the diuretic component is associated with an increased risk of Non-Melanoma Skin Cancer (NMSC) [1.7].
Safety-related restrictions or limitations	Contraindications include hypersensitivity to the components or sulfonamide-derived drugs, and co-administration with aliskiren in diabetic patients [1.1].

Resulting Safety Structure

The official safety information structures the understanding of risks by systematically separating frequent, generally non-serious reactions from rare, serious adverse events. The documentation of specific contraindications and safety limitations defines the conditions under which the use of the medicine is formally restricted, as established by government regulators [1.1, 1.7].

Overdose and Emergency Response

The official regulatory documentation for Tiartan (Eprosartan/Hydrochlorothiazide) describes overdose manifestations stemming from excessive blood pressure lowering and severe fluid loss.

Documented Overdose Manifestations

The primary documented signs of overdose include profound hypotension (dangerously low blood pressure) and signs of severe volume depletion, which can lead to light-headedness, syncope (fainting), and shifts in heart rate (either fast or slow). Due to the diuretic component, overdose often presents with electrolyte imbalance, which may cause central nervous system effects such as drowsiness and confusion. Gastrointestinal symptoms like nausea and vomiting may also occur, exacerbating volume loss.

Overdose is classified as potentially severe or life-threatening due to the risk of Acute Renal Failure secondary to low perfusion, or the precipitation of hepatic coma in predisposed patients. The Hydrochlorothiazide component carries a rare, documented risk of Acute Respiratory Distress Syndrome (ARDS).

When to Seek Help

Official labeling mandates that immediate medical attention must be sought for any suspected overdose. Emergency services (911 or equivalent) must be called immediately if the person has collapsed, is having a seizure, is unconscious, or is experiencing trouble breathing. No specific antidote is known, and clinical management requires symptomatic and supportive treatment with close monitoring of vital signs, serum electrolytes, and renal function. The risk of severe outcomes is noted to be higher in patients with severe cardiac insufficiency or bilateral renal artery stenosis.

Therapeutic Uses of Tiartan

What Tiartan Treats: Main Uses and Benefits

Tiartan (Eprosartan/Hydrochlorothiazide) is a fixed-dose combination medicine used for the long-term management of high blood pressure (essential hypertension). Its primary purpose is applied in addressing the symptoms related to systemic imbalance and the associated long-term cardiovascular risks. The combination is commonly used when the patient's blood pressure requires management beyond a single medication.

Therapeutic Context and Benefits

The combination is primarily used for managing symptoms related to heightened physiological activity (persistently elevated readings), and scenarios where initial monotherapy is not maintaining stable pressure readings. This medication is used for managing these elevated readings, which contributes to easing the overall symptom load linked to organ-specific functional stress caused by chronic hypertension. It supports the patient during episodes of heightened physiological stress and may assist with maintaining functional stability.

QuickFact Block

Quick Fact: Relief for Elevated Pressure	Description
Primary Therapeutic Goal	Is used for managing persistently high systemic pressure readings
Clinical Scenario	Applied in clinical settings where additional symptomatic support is needed beyond a single medication
Patient Benefit	Contributes to easing the symptom load linked to organ-specific functional stress
Severity Relevance	Relevant in conditions characterized by moderate-to-severe symptoms related to systemic imbalance

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Tiartan — official regulatory information

Eligibility scope

Populations for whom use is allowed (as stated in label): Adults.

Populations for whom use is contraindicated:

Patients with a known hypersensitivity to the active substance or any product component.
Pregnant patients.
Patients with diabetes who are also taking an Angiotensin Converting Enzyme Inhibitor (ACEI) or an Angiotensin Receptor Blocker (ARB).
Patients with severe hepatic impairment.

Age-related eligibility rules:

Use in the pediatric population is not established.

Condition-specific eligibility rules:

Renal Impairment: Coadministration with an ACEI or ARB should be avoided in patients with moderate to severe renal impairment (glomerular filtration rate [GFR] < 60 mL/min).

Pregnancy and lactation eligibility status:

Pregnancy: Contraindicated.
Lactation: Use is not recommended as it is unknown if the medicine is excreted in human milk, and a decision must weigh the drug's importance to the mother against potential risk to the nursing infant.

Connection to the overall eligibility profile

Official regulatory documents define non-eligible populations for Tiartan primarily through absolute contraindications that prohibit use, such as for pregnancy and in cases of known hypersensitivity. The label further restricts use by prohibiting coadministration with other cardiovascular drug classes (ACEIs/ARBs) in specific groups, including patients with diabetes or those with moderate to severe renal impairment. These official classifications outline the boundaries of patient eligibility to ensure proper therapeutic use based on known safety profiles.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tiartan, a fixed-dose combination of Eprosartan and Hydrochlorothiazide, has officially documented interaction patterns primarily concerning blood pressure regulation, electrolyte balance, and drug absorption.

Official Interaction Statements

Interacting Substance/Class	Official Documented Interaction Pattern
Aliskiren	Contraindicated in patients with diabetes mellitus due to increased risks of severe hypotension, hyperkalemia, and worsening kidney function (dual RAAS blockade).
Lithium	Co-administration may increase serum lithium concentrations and the risk of toxicity because the Hydrochlorothiazide component reduces Lithium's renal clearance.
Potassium Supplements & K-Sparing Diuretics	Co-administration may result in hyperkalemia (elevated serum potassium levels), primarily due to the Eprosartan component.
NSAIDs (e.g., COX-2 inhibitors)	May reduce the antihypertensive effects of Tiartan and pose a risk of worsening renal function in susceptible patients.
Cholestyramine & Colestipol	These resins significantly impair the absorption of Hydrochlorothiazide, necessitating administration to be separated by several hours to maintain drug exposure.
Alcohol	May potentiate the orthostatic hypotensive effect associated with the Hydrochlorothiazide component.

Pharmacokinetic and Population Notes

The Eprosartan component is officially noted to not be metabolized by the Cytochrome P450 system, which limits the potential for complex metabolic drug-drug interactions. In patients with moderate or severe renal impairment, official data indicates that Eprosartan exposure (AUC) is significantly increased, altering its pharmacokinetic profile within this population. Dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS), such as with an ACE inhibitor, is not generally recommended.

Mechanism of Action

How Tiartan Works

Receptor and Enzyme Modulation

Tiartan's mechanism begins with selective engagement with a specific receptor or enzyme system, initiating an effect on regulatory processes. By binding to its defined biological target, Tiartan is used to initiate or block specific signaling events, which is the first step in modulating signaling associated with heightened activity.

Influence on Molecular Pathways

Following the initial binding, Tiartan acts within well-characterized molecular cascades to alter signaling dynamics. This involves mechanism-driven modulation of signal transduction, particularly in pathways characterized by heightened activation. Tiartan helps to modulate excessive signaling and supports the regulation of physiological responses by modifying the flow of biological information.

Systemic Pathway Influence

The effect of Tiartan on the molecular pathways culminates in a systemic influence that adjusts activity within central or peripheral pathways. This contributes to regulating the magnitude of physiological responses and reducing the activity of excessive mediators. This action supports a more regulated state within the affected systems, which result in physiological adjustments that characterize the drug's mechanism of action.

Dosage and Administration Information

Tiartan (Eprosartan/Hydrochlorothiazide) is administered exclusively by the oral route as a film-coated, non-scored tablet. This fixed-dose combination is available in two main strengths: 600 mg of Eprosartan paired with either 12.5 mg or 25 mg of Hydrochlorothiazide.

The standard adult regimen involves taking one tablet once daily. The typical starting dose is the 600 mg/12.5 mg strength, particularly for patients whose condition was not adequately managed by eprosartan alone. The maximum recommended daily dose for this combination is defined as one 600 mg/25 mg tablet. For consistent use, the medication may be taken with or without food, but administration should occur in the morning.

Dosage adjustment, or titration, may be considered by a healthcare professional after the patient has completed an initial period of therapy, generally after two to three weeks of the starting regimen, based on the response.

Specific considerations apply to different populations. For instance, in cases of moderate to severe renal impairment, the total daily dose of the Eprosartan component should not exceed 600 mg. Conversely, no specific dose adjustment is deemed necessary for older adults or for individuals with hepatic impairment. The safety and effectiveness of Tiartan have not been established for use in pediatric patients under 18 years of age.

Recent Clinical Evidence

The research on Tiartan, the fixed-dose combination of Eprosartan and Hydrochlorothiazide, primarily consists of official clinical evaluations that have studied the product in adults who have essential hypertension (high blood pressure). These studies help show what has been observed so far regarding this combination treatment, according to regulators and peer-reviewed scientific literature.

Evidence for Use in Managing Essential Hypertension

Research examined the use of this combination in adults with essential hypertension. The available evidence is derived from Randomized Controlled Trials (RCTs), where people are randomly assigned to receive the combination medicine, the single Eprosartan component (monotherapy), or a placebo. These short-term studies explored the changes over the defined trial interval in key physical readings, focusing on systolic and diastolic blood pressure.

Study Focus: Blood Pressure Reduction and Comparison to Monotherapy

In the short-term trials, research examined how blood pressure measurements evolved when the combination was used compared to when patients were only taking Eprosartan alone. Findings described patterns where patients receiving the combined agents had different measured outcomes in the upper and lower blood pressure readings when compared to Eprosartan monotherapy. Furthermore, studies explored the percentage of patients who reached a specific target blood pressure goal defined by the researchers.

Long-Term Studies and Sustained Study Measurements

To understand the treatment beyond short-term observations, researchers were observed in longer-term open-label trials and extended follow-up studies, sometimes lasting up to 2.5 years. This type of research was evaluated for tracking blood pressure measurements over extended timeframes and observing long-term patterns related to predefined endpoints such as cardiovascular and cerebrovascular events. Data for the fixed-dose combination's sustained study measurements are largely extrapolated from trials of the Eprosartan component itself.

What Is Still Uncertain About the Research for Tiartan

Despite the available evidence, certain aspects remain not fully established. The primary evidence comparing the combination to the single agent comes from studies that had limited follow-up durations. Additionally, there is limited long-term data on major cardiovascular events specifically for the fixed-dose combination. Dedicated, long-term RCTs on the fixed-dose combination itself to assess major cardiovascular events over many years have not yet been reported.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Tiartan (FAQ)

Q: Is Tiartan considered a first-line treatment for its indicated use?

According to patient guidance derived from official regulatory texts, this combination drug is generally not used as a first medicine to treat high blood pressure. It is often prescribed when other medications have not adequately controlled the condition or have caused unwanted effects. This position in treatment reflects its designation as a combination product.

Q: What is the purpose of taking Tiartan long-term?

Official information indicates that Tiartan is used specifically to control high blood pressure; it is not intended to cure the condition itself. For the management of chronic high blood pressure, taking medication typically involves doing so on a long-term basis to ensure continued blood pressure control and help mitigate long-term systemic strain.

Q: How quickly does Tiartan usually begin to show an effect?

The combined medicine acts in two ways. The diuretic component, hydrochlorothiazide, begins to increase urine flow within two hours. However, the full blood pressure reduction from the eprosartan component is generally achieved over a period of two to three weeks of consistent treatment.

Q: Does Tiartan have a delayed onset of action, and why?

Yes, official product information suggests a delayed therapeutic onset. The maximum blood pressure-lowering effect of the eprosartan component builds up over a period of two to three weeks. Consistent use over this time frame is often observed to reach the full regulatory effect.

Q: Is it common to not notice Tiartan working right away?

Yes, it is common. Since the full blood pressure reduction often takes two to three weeks to be achieved, patients are not expected to notice the full therapeutic effect immediately after starting the medication. Blood pressure is monitored by a healthcare professional to assess the medicine’s effectiveness.

Q: How long does the effect of one dose of Tiartan last?

Official pharmacokinetic data shows the mean terminal elimination half-life (the time it takes for half the medicine to leave the body) is approximately 20 hours for the eprosartan component. The hydrochlorothiazide component's half-life varies between 5.6 and 14.8 hours. These half-life values are consistent with the product's once-daily dosing schedule.

Q: Do patients need special monitoring or blood tests while taking Tiartan?

Yes, official product information recommends monitoring certain body functions. Before starting treatment and at intervals during therapy, blood and urine tests may be necessary. Tests are used to check for changes such as unwanted electrolyte imbalances, renal function, and uric acid levels.

Q: Is Tiartan safe for people with kidney problems?

The official documentation advises that Tiartan should be used with caution in patients who have kidney impairment. The medicine's components can affect fluid and electrolyte balance, and the product is strictly contraindicated (not allowed) in patients with anuria (the inability to pass urine). Assessment by a healthcare professional is necessary to evaluate the risks.

Q: Does taking Tiartan make you feel dizzy or drowsy?

Official safety data lists dizziness as a common side effect. Drowsiness has also been reported as a possible side effect in some patients. You should be aware of these potential effects, especially when first starting treatment.

Q: Is it normal to feel nausea when starting Tiartan?

Official regulatory documents list nausea under the category of gastrointestinal disorders that have been reported by users. While specific frequency may vary, unspecific gastrointestinal complaints are not uncommon when beginning this type of treatment.

Q: Are there any specific foods that must be avoided while taking Tiartan?

Official regulatory prescribing information states that this medicine may be taken with or without food. There are no specific foods or dietary timing restrictions that must be avoided while using this medication.

Q: Is the generic version of Tiartan the same as the brand name?

Regulatory bodies must approve generic products to be therapeutically equivalent to the brand-name product, meaning they are expected to work the same way in the body. However, specific regulatory statements on the equivalence of this drug are not addressed in the official clinical label.

Q: Is Tiartan used to treat more than one condition?

The general therapeutic purpose of Tiartan, as listed in the official documents, is the management of essential hypertension (high blood pressure). It is not listed as being indicated for the treatment of other authorized diseases.

Q: Does Tiartan affect the ability to drive or operate machinery?

Official product information advises caution. It should be taken into account that side effects such as dizziness or weariness (fatigue) may occasionally occur. These effects could impact a person's ability to drive vehicles or safely operate heavy machinery.

Q: What happens if I miss a dose of Tiartan? (Informational only)

Regulatory patient guidance describes a general procedure for missed doses. This procedure typically involves taking a dose when remembered unless it is near the next scheduled dose, in which case the missed dose is skipped. It is documented that missed doses should not be doubled.

Q: What is the half-life of Tiartan?

The half-life refers to the time it takes for half of the active substance to be eliminated from the body. Official pharmacokinetic data shows the mean terminal elimination half-life of the eprosartan component is approximately 20 hours, while the hydrochlorothiazide component ranges from 5.6 to 14.8 hours.

Q: Does Tiartan carry a Boxed Warning from the FDA, and what does it mean?

Yes, official FDA documents state that the product carries a Boxed Warning (the agency’s highest safety warning) regarding use during pregnancy. The warning describes that drugs acting on the renin-angiotensin system can cause injury and even death to the developing fetus if used during the second and third trimesters of pregnancy.

Q: How is Tiartan typically eliminated from the body?

Regulatory documents describe two main routes of elimination. The eprosartan component is eliminated from the body primarily through both the biliary system (bile) and the kidneys (urine). The hydrochlorothiazide component is not metabolized and is eliminated rapidly and entirely via the kidney.

Q: Can patients who have had allergic reactions to other drugs use Tiartan?

Official regulatory texts list specific contraindications. The product is strictly contraindicated if a person has a known hypersensitivity to the active substances or to any drug that is sulfonamide-derived (due to the hydrochlorothiazide component). Assessment by a healthcare professional is necessary to evaluate the risk of a prior drug allergy.

Q: Is Tiartan suitable for patients with autoimmune conditions?

Regulatory cautions advise using this medication with care in patients with Systemic Lupus Erythematosus (SLE), a specific autoimmune condition, as official information suggests it may potentially make the condition worse. Information on other autoimmune conditions is not specifically addressed in the regulatory documents.

Q: Does Tiartan have any known long-term effects?

The official safety profile outlines risks associated with long-term exposure. Regulatory warnings state that long-term exposure to the diuretic component (hydrochlorothiazide) is associated with an increased risk of Non-Melanoma Skin Cancer (NMSC). Other long-term effects are monitored through continued surveillance.

How should Tiartan be stored and disposed of?

How to Store and Dispose of Tiartan (Eprosartan/Hydrochlorothiazide)

Tiartan tablets must be stored according to official regulatory requirements to maintain their quality and strength.

Storage Requirements

Tiartan must be stored below 25°C and protected from excess heat and moisture. The medicine must be kept in its original packaging and the container should be tightly closed to ensure stability.

Storage in environments like the bathroom or near a sink is prohibited, and the tablets must not be used past the printed expiry date.

Child Safety and Disposal

It is mandatory to store Tiartan out of the sight and reach of children.

Disposal of expired or unused tablets should follow local guidelines. The product must not be thrown into household wastewater or the sewage system. Users should return unused medicine to a pharmacist or utilize an authorized drug take-back program.

Tiartan